<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105969">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02010762</url>
  </required_header>
  <id_info>
    <org_study_id>NL.45391.018.13</org_study_id>
    <nct_id>NCT02010762</nct_id>
  </id_info>
  <brief_title>The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease</brief_title>
  <acronym>DETECT</acronym>
  <official_title>The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease: a Placebo-controlled Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>European Union: European Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The majority of patients with Crohn's disease (CD) need to undergo surgical bowel resection.
      Postoperative recurrence of the disease is virtually inevitable and continues to be one of
      the most challenging therapeutic problems in inflammatory bowel diseases. Medical treatments
      to prevent recurrence have had limited effect. Anti-tumor necrosis factor (TNF) agents
      appear promising but are hampered by immunogenicity, side effects and high cost.

      Vitamin D has recently received a lot of scientific attention and was found to have strong
      anti-inflammatory and antifibrotic effects in gut and liver inflammation. Many CD patients
      appear to have deficiency in Vitamin D. A controlled trial to prevent relapse of CD in
      medical (not surgical) remission suggested a preventive effect for Vitamin D but marginally
      missed its endpoint because of lack of power.

      The ultimate proof of the anti-inflammatory effect of Vitamin D in CD can best be studied in
      the prevention of postoperative recurrence.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Proportion of patients with clinically significant endoscopic recurrence at 6 months of vitamin D3 treatment postoperatively, defined as endoscopic Rutgeerts' score ≥i2.</measure>
    <time_frame>0-6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Clinical CD recurrence measured with CDAI among the 2 groups at week 26 (CDAI ≥220)</measure>
    <time_frame>0-6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. NOD2 gene mutations: the difference in response to vitamin D treatment in patients NOD2+ versus patients NOD2-.</measure>
    <time_frame>0-6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3. Difference in significant recurrence among all patients with low vitamin D at baseline</measure>
    <time_frame>0-6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4. Quality of life, measured by one validated questionnaire for IBD patients (IBD-Q) and two general questionnaires (SF-36 and EuroQol)</measure>
    <time_frame>0-6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5. Any adverse events</measure>
    <time_frame>0-6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weekly Vitamin D3 drops 25.000 IU for 6 months following ileocoecal resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Weekly placebo drops for 6 months following ileocoecal resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>25.000 IU oral drops</description>
    <arm_group_label>Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo oral drops</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years, either male or female

          -  Established CD

          -  First or second ileocolonic resection with ileocolonic anastomosis and removal of all
             tissue macroscopically affected by CD according to the surgeon

          -  Able to give written informed consent

          -  Normal levels of serum calcium at inclusion

          -  Being able to resume oral intake within 2 weeks after surgery

        Exclusion Criteria:

          -  Patients in whom not all visible CD has been resected

          -  Active fistulizing perianal disease (requiring anti TNF treatment)

          -  Extensive small bowel resection

          -  Third, fourth or later ileocolonic resection

          -  Patients undergoing ileocoecal resection in the Lir!c Trial (NTR 1150,
             http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1150)

          -  A history of primary hyperparathyroidism

          -  A history of osteoporosis for which calcium and Vitamin D treatment are mandatory

          -  A history of another granulomatous diseases (sarcoidosis, tuberculosis)

          -  Pregnant or breastfeeding (at index date) female patients

          -  Patients undergoing other resections than ileocolonic resections

          -  Patients who prefer to use open-label vitamin D preparations

          -  Patients who will continue to use tanning beds
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert D'Haens, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica de Bruyn, MD</last_name>
    <phone>0031205668873</phone>
    <email>j.r.debruyn@amc.uva.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Geert D'Haens, MD, PhD</last_name>
    <phone>0031205661768</phone>
    <email>g.dhaens@amc.uva.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 BK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica de Bruyn, MD</last_name>
      <phone>0031205668873</phone>
      <email>j.r.debruyn@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Geert D'Haens, MD, PhD</last_name>
      <phone>0031205661768</phone>
      <email>g.dhaens@amc.uva.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 10, 2013</lastchanged_date>
  <firstreceived_date>December 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Geert D'Haens</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Crohn's disease</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Postoperative</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Inflammatory bowel disease</keyword>
  <keyword>Gastroenteritis</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Colonic Diseases</keyword>
  <keyword>Intestinal Diseases</keyword>
  <keyword>Pathologic Processes</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
